KAICO selected for Fukuoka City's new startup support initiative, “High Growth Program”
KAICO Co., Ltd. was selected for Fukuoka Growth Next (FGN), Fukuoka City's public-private startup support facility.

KAICO produces recombinant proteins and vaccines using a silkworm-baculovirus expression system.
kaicoltd.jpCrawled Oct 15, 2026
KAICO Co., Ltd. was selected for Fukuoka Growth Next (FGN), Fukuoka City's public-private startup support facility.
The page features the promotional video “Changing the world with silkworms,” dated October 2024, by the Director General of the Thailand National Innovation Agency.
KAICO Co., Ltd. was selected as a company supported by JETRO (Japan External Trade Organization) for the Japan Pavilion.
KAICO Co., Ltd. will participate in Interphex Week at Makuhari Messe from May 20 to 22, 2026.
KAICO Co., Ltd. will participate in IPVS 2026, held in Ho Chi Minh City, Vietnam, from June 16 to 19, 2026.
KAICO Co., Ltd. is promoting a partnership to begin demonstration trials in Thailand and commercialize the product in Taiwan.
KAICO Co., Ltd. signed a basic sales agreement with Reber Genetics and is advancing product registration in Taiwan.
KAICO Co., Ltd. introduces its team.
An introduction to KAICO Co., Ltd. and its company overview.
This is the Company page of KAICO Co., Ltd. It introduces the company, team, and sustainability initiatives.
KAICO Co., Ltd. was established in Kyushu in April 2018 to develop pharmaceuticals, diagnostics, and reagents using hard-to-express proteins.
The company is working on a project to revive the sericulture industry that combines contributions to the global environment with regional revitalization.
KAICO株式会社 is a biotech venture spun out of Kyushu University. Using proteins produced through its proprietary silkworm–baculovirus expression method, the company aims to bring silkworm-produced medicines and vaccines to the world.
This is the privacy policy page for KAICO株式会社.
This page outlines the guidelines for quoting and linking to KAICO株式会社.